[Communiqué officiel] À l’occasion du déplacement du Président de la République française, Emmanuel Macron, XENOTHERA est présente en Chine pour suivre un programme Business organisé par Business France.
April, 2026. In collaboration with CR2TI in Nantes (Center for Research in Transplantation and Translational Immunology), XENOTHERA presented the anti-cancer activity of XON11, its innovative treatment targeting pancreatic cancer, derived from its GH-pAbs technology platform (glyco-humanized polyclonal antibodies), at the Cancer Research Center of Marseille Congress.
October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications
June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone
